Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-XBI-302 in Glucocorticoid-refractory Acute GVHD
NCT05094765Phase 1Unknown
- Sponsor
- Xbiome
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 1, open-label, single-arm trial of XBI-302 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Xbiome. Primary endpoints: Objective Response Rate at Day 28 and Adverse Events at Day 28. Status: unknown.
02
Drugs
XBI-302
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05094765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094765.